Market for Rheumatoid Arthritis Treatments to Reach $13 bn by 2011, Says New Report Available From Piribo
Piribo, the online destination for business intelligence for the biotech and pharmaceutical industry, has just added to its collection a key market report, Rheumatoid Arthritis Therapeutics.
(PRWEB) September 27, 2006 -- Piribo, the online destination for business intelligence for the biotech and pharmaceutical industry, has just added to its collection a key market report rheumatoid arthritis therapeutics.
This market has experienced remarkably strong growth during the past five years due to the introduction of the biological response modifiers (BRMs) to treatment regimens. The value of this market will reach nearly $13 billion by 2011.
Rheumatoid Arthritis Therapeutics: Market Trends and R&D Insights (http://www.piribo.com/search/results.html?k=arr015&x=0&y=0 ) says that sales of both Remicade and Enbrel continue to grow, while the introduction of Humira in 2003 has been a major stimulus to the market. All three of these products are now approved in both the US and Europe for rheumatoid arthritis. Added to this mix in 2006 was Rituxan and Orencia, which will both have an impact in the patient population unresponsive to other BRMs. As half-year 2006 revenues clearly indicate, revenues from the sales of all of these products will continue to trend positively in 2007.
The rheumatoid arthritis pipeline today is replete with biologic therapies designed to modify the course of the disease. There are a number of follow-on biologic products being developed, which, like Remicade, Enbrel and Humira, target TNF-a. Additionally, though, companies are investing in candidates which target other cytokines that have been implicated in disease development.
The 95 page report is arranged to provide readers with an analytically-based overview of the market for rheumatoid arthritis therapies as well as an assessment of therapeutics currently in clinical development. The report focuses primarily on the class of rheumatoid arthritis therapeutics known as the biological response modifiers (BRMs). These drugs currently account for the vast majority of sales in this therapeutic area and will continue to make a strong impact in the coming years.
Key features of this report:
- An assessment of the current status of key products on the market and emerging products with significant growth potential.
- Analysis of key clinical trials as a means of determining future success in the market
- Forecast financial growth of this sector as a whole as well as provide revenue forecasts for key products in the field (all forecasts through 2011)
- Identification of trends and issues that will have a significant impact on the rheumatoid arthritis market
- Important background about the disease, its etiology, patient population and financial impact of RA
“Rheumatoid Arthritis: Market Trends and R&D Insights” is available in PDF format from Piribo. For more information, go to: http://www.piribo.com/publications/diseases_conditions/rheumatoid_arthritis_market.html
About Piribo.
Piribo is a UK-based independent online store supplying business information on the pharmaceutical and biotechnology industries. The website now carries over 3,800 English language titles including market reports, studies and books and is the UK’s largest online biopharma information store. Subscribers receive a free monthly newsletter and e-mail alerts on new titles in their areas of interest. The company was established in 2004. Piribo also owns Report Buyer (http://www.reportbuyer.com).
###
|
